Interestingly, the combination of the anti-IGF1R mAb ganitumab with the SFKs inhibitor dasatinib is being currently tested in patients affected by rhabdomyosarcoma, both alveolar and embryonal subtypes (NCT03041701). This evidence concerns the gene IGF1R and rhabdomyosarcoma.